Product Details: Glycine

Glycine DISCUSSION: Glycine is the simplest of all amino acids required for protein synthesis in the body. Research supports a role for glycine in supporting a wide range of bodily structures and functions, including release of somatotropin (human growth hormone), memory function, healthy thought patterns, collagen synthesis, normal cell growth and development, glucose metabolism after a carbohydrate load, and preventing unhealthy angiogenesis (blood vessel formation).
500 grams AOR04065
100% Vegetarian

SUPPLEMENT FACTS:
Serving Size: 1 Tablespoon


    %DRI
Glycine ~15g *

*Dietary Reference Intake not established.
Other ingredients: none.

AOR guarantees that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, corn, nuts, dairy, soy, eggs, fish or shellfish.

Suggested Use
For healthy thought patterns or healthy cell development and blood vessel formation, take 15-60 g (~ 1-4 T). For general healthy brain function, dissolve 5 g (~1 tsp) under your tongue and hold for one minute twice daily. For hGH release, dissolve 5 g (~1 tsp) under your tongue and hold for one minute, 45 minutes before bed, breakfast, or exhaustive weight-bearing exercise. For the above uses, take on an empty stomach. For healthy metabolism of meal carbohydrates, take 5 g after a meal. Or as directed by a qualified health consultant.

Main Applications
As reported by literature:
• Cognitive support.
• Neuroprotection.
• Cytoprotection.
• Supports normal cell growth and differentiation
• Supports healthy thought patterns
• Supports growth hormone release
• Supports healthy glucose metabolism
• Supports bone health

Source
pharmaceutical synthesis.

Pregnancy / Nursing
Safe at 2 g/day.

Cautions
None.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide medical advice to individuals. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes. Any reproduction in whole or part and in print or electronic form without express permission is strictly forbidden. Permission to reproduce selected material may be granted by contacting AOR Inc.

Copyright © 2005, Advanced Orthomolecular Research 

 


Glycine Glycine is the smallest and simplest of amino acids: its structure is so straightforward that it doesn't even have ‘D-' and ‘L-' forms. And although it's the second most-used amino acid in the biosynthesis of proteins and enzymes, and despite the fact that it's essential for the phase-II detoxification of many xenobiotics, and for the body's manufacture of such critical biomolecules as nucleic acids, the high-energy carrier creatine phosphate, and the key antioxidant glutathione (GSH), glycine has largely been neglected as a readily-available and "non-essential" nutrient. But all that has changed in the last few years. Recent reviews in the scientific literature have had titles like "Glycine - an inert amino acid comes alive" and "L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent." As research into this conditionally-essential amino acid has progressed, the health impacts associated with the real limits of availability of glycine - and the benefits of supplementation well above the levels readily available from the diet - have become increasingly clear. Glycine is emerging as a critical unsung hero of human nutrition for brain and body.

Glycine, NMDA, and Memory
The importance of the N-methyl-D-aspartate (NMDA) receptor to memory was shown dramatically with the "Doogie" mouse, which has an extra copy of one subcomponent of the receptor. These mice have a significantly boosted performance on a wide range of learning and memory tasks, including an improved ability to solve mazes, to learn from the sights and sounds in their environment, and to retain that knowledge; perhaps more importantly, they retain superior memory into ages when memory in normal mice is falling.

The problem with the NMDA receptor is that its main activator is glutamate, an excitatory amino acid with a dark side. Excessive stimulation of the NMDA receptor by glutamate causes a deadly overstimulation of the neuron called excitotoxicity, which eventually burns the brain cell out. Overactivation of the glutamate site is believed to underlie a great deal of the damage wrought on brain cells in Alzheimer's disease, Parkinson's disease, strokes, and other neurological disorders.

Neurodegenerative conditions
Fortunately, there is another site on the NMDA receptor complex which allows for the safer activation of this key receptor. This "co-agonist" site is activated by Glycine instead of glutamate. Unlike the glutamate binding site, activating the glycine binding site does not trigger the opening of the receptor - but the receptor can't open if the site is not activated. Studies in humans and animals show that glycine itself - or drugs that work by activating the glycine co-agonist site, such as Milacemide - enhance long-term potentiation of memory, without producing neurotoxicity.

In one randomized, double-blind, placebo-controlled trial, a glycine sublingual formulation was tested for its effects on memory in healthy students and in middle-aged men. The sublingual glycine formulation "significantly improved retrieval from episodic memory" in all subjects; glycine also significantly improved sustained attention in the middle-aged participants. The researchers noted that the effects of glycine were unique, because they don't involve a stimulant effect and don't affect mood, and suggest that sublingual glycine "is likely to be of benefit in ... situations where high retrieval of information is needed or when performance is impaired by jet lag, shift work, or disrupted sleep."

While special glycine formulations or prodrugs are effective at only a few hundred milligrams, glycine itself has a hard time crossing the blood-brain barrier. Experimenting with from five to ten grams - and more, up to a maximum of 60 grams in divided doses - held under the tongue for a minute before swallowing, should tell you if glycine will do the trick for you, and at what doses.

Glycine, NMDA, and Schizophrenia
The first hints of the importance of glycine in schizophrenia came from the discovery that Phencyclidine ("angel dust" or PCP - a nasty street drug which causes serious schizophrenic-like hallucinations in healthy people and worsens symptoms in schizophrenics even if they have gone into remission) - does its damage by blocking the glycine modulatory site on the NMDA receptor. Interest quickened when it was found that glycine could reverse most of the behavioral and neurochemical abnormalities in animals administered PCP.

Several trials have now shown that high-dose glycine supplementation improves the "negative symptoms" of schizophrenia (such as "flat" emotional expression, depression, poverty of speech, apathy, and social withdrawal). This is an important result, since most schizophrenia medications only affect the "positive symptoms" of the disease, such as the hallucinations. Glycine also appears to boost the efficacy, and reduce the side-effects, of some schizophrenia medications. (One exception is the drug clozapine, perhaps because the drug itself may work by modulating the NMDA receptor). Limited success has been observed at doses of 10 grams per day; better results are seen at 30 or 60 grams.

Glycine and Growth Hormone (hGH)
In addition to is exciting potential for supporting the healthy functioning of the brain, Glycine may provide us with part of the key to reversing some of the more visible symptoms of the aging body. For some time, research has been focusing in on the age-related loss of human growth hormone (hGH, or somatotropin) as a major source of the symptoms of aging. hGH helps keep our bones strong, our immune systems vigorous, our wound-healing abilities optimal. It builds muscle and burns fat. Its levels are high in our youth, when all of these functions are at their peak, and their decline follows the decline in many aspects of youthful function. As experiments by Dr. Daniel Rudman and others have shown, administration of hGH to aging humans can bring about changes in body composition which are "equivalent in magnitude to the changes incurred during 10-20 years of aging."

While many substances are touted as hGH precursors or secretagogues, few are actually documented to boost levels of the hormone - and of those that are, many are marketed in formulas in which they are mixed in with other factors that blunt their effectiveness, or are only effective at doses significantly higher than the recommended dose. But less than 6 grams of glycine has been shown to more than triple hGH levels in normal, healthy men and wormen. This effect is again likely connected to glycine's role as a coagonist of the NMDA receptor.

Glucose Metabolism
The surge of blood sugar that happens following a meal - especially one high in carbohydrates and/or in glycemic index - is a metabolic roller coaster, leading to sugar ‘highs' and crashes, carb cravings, metabolic dysregulation, and ultimately insulin resistance and ill-health. Finding new ways to control this post-meal jump in blood sugar is an important part of maintaining our health.

A recent study suggests that Glycine may be the next tool at our disposal to keep blood sugar on an even keel. In this study, healthy men and women were tested on four separate occasions, in which they were given 25 grams of glucose alone; glucose with 5 grams of glycine; glycine alone; or plain water. The plain glucose, unsurprisingly, rushed into the volunteers' bloodstreams, leading to a huge blood sugar ‘spike;' but glycine supplementation reduced the total increase in blood glucose by a remarkable 50%. Importantly, this channeling of the glucose surge was not accompanied by any increase in insulin levels, nor did it push fasting glucose levels down into hypoglycemia: the mechanism remains unknown, and the effect was so distinct from other glucose-lowering agents that the researchers who reported the result even speculate that the result may lead to the discovery of a new gut hormone regulating glucose metabolism.

Cancer
Researchers at the Curriculum in Toxicology at the University of North Carolina, Chapel Hill, have reported some impressive results using high-dose glycine to fight the scourge of cancer. In one study, experimental animals were fed diets containing the carcinogenic drug WY-14643 along with conventional lab chow or glycine-supplemented diets. Glycine had no effect on the microhormonal effects of the drug, or on the incidence or numbers of early, abnormal cell lesions in the animals' livers. But nearly a year later, as the animals were developing actual tumors, glycine supplementation prevented the formation of small, medium, and large liver tumors by 23%, 64%, and an astonishing 80%, respectively! In other words, glycine demonstrated the power to directly inhibit the progression of early, precancerous lesions into full-blown tumors.

In a later study, the UNC researchers expanded these findings and identified one possible mechanism for the remarkable anti-cancer effects they had observed. In this experiment, laboratory animals were implanted with melanoma tumors and given either conventional diets or a diet supplemented with high-dose glycine. The scientists watched as the tumors grew rapidly in the animals eating the conventional diets - but in those consuming the supplemental glycine, tumors were 50 to 75% smaller; likewise, the tumors weighed about two-thirds less in animals benefiting from the glycine supplements.

To find out what was going on, the scientists tried growing the cancer cells in test tubes containing increasingly high doses of glycine, to no effect. Instead, as researchers discovered after implantation, glycine slows the growth of these cancer cells by inhibiting angiogenesis - the process by which cancers attract new blood vessels to themselves to feed their uncontrolled growth.

Good Things Come in Small Packages
We haven't had space to discuss the many other new discoveries about glycine made in the last few years: its cytoprotective, immunomodulating, and antithrombotic effects; its suppression of inflammatory responses in some immune cells; its ability to protect the brain from stroke damage and help the brain heal after a stroke; the animal evidence supporting glycine's ability to help the liver heal after liver fibrosis and improve outcomes after organ transplantation; the importance of glycine in bone health; or its role as an extracellular signaling molecule, regulator of ion channels. In packing so many benefits into so small a biomolecule as glycine, Nature seems to have been following the "KISS" rule: "Keep It Simple, Stupid."

References

Zhong Z, Wheeler MD, Li X, Froh M, Schemmer P, Yin M, Bunzendaul H, Bradford B, Lemasters JJ. L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care. 2003 Mar;6(2):229-40.

File SE, Fluck E, Fernandes C. Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults. J Clin Psychopharmacol. 1999 Dec;19(6):506-12.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999 Jan;56(1):29-36.

Kasai K, Kobayashi M, Shimoda SI. Stimulatory effect of glycine on human growth hormone secretion. Metabolism. 1978 Feb;27(2):201-8.

Rose ML, Cattley RC, Dunn C, Wong V, Li X, Thurman RG. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643. Carcinogenesis. 1999 Nov;20(11):2075-81.


The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide medical advice to individuals. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes. Any reproduction in whole or part and in print or electronic form without express permission is strictly forbidden. Permission to reproduce selected material may be granted by contacting AOR Inc.

Copyright © 2005, Advanced Orthomolecular Research

 


L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent.
Curr Opin Clin Nutr Metab Care. 2003 Mar; 6(2): 229-40.
Zhong Z, Wheeler MD, Li X, Froh M, Schemmer P, Yin M, Bunzendaul H, Bradford B,
Lemasters JJ.

PURPOSE OF REVIEW: In recent years, evidence has mounted in favor of the antiinflammatory, immunomodulatory and cytoprotective effects of the simplest amino acid L-glycine. This article will focus on the recent findings about the responsible mechanisms of protection and review the beneficial effects of glycine in different disease states.
RECENT FINDINGS: Glycine protects against shock caused by hemorrhage, endotoxin and sepsis, prevents ischemia/reperfusion and cold storage/reperfusion injury to a variety of tissues and organs including liver, kidney, heart, intestine and skeletal muscle, and diminishes liver and renal injury caused by hepatic and renal toxicants and drugs. Glycine also protects against peptidoglycan polysaccharide-induced arthritis and inhibits gastric secretion and protects the gastric mucosa against chemically and stress-induced ulcers. Glycine appears to exert several protective effects, including antiinflammatory, immunomodulatory and direct cytoprotective actions. Glycine acts on inflammatory cells such as macrophages to suppress activation of transcription factors and the formation of free radicals and inflammatory cytokines. In the plasma membrane, glycine appears to activate a chloride channel that stabilizes or hyperpolarizes the plasma membrane potential. As a consequence, agonist-induced opening of L-type voltage-dependent calcium channels and the resulting increases in intracellular calcium ions are suppressed, which may account for the immunomodulatory and anti-inflammatory effects of glycine. Lastly, glycine blocks the opening of relatively non-specific pores in the plasma membrane that occurs as the penultimate event leading to necrotic cell death.
SUMMARY: Multiple protective effects make glycine a promising treatment strategy for inflammatory diseases.


Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults.
J Clin Psychopharmacol. 1999 Dec; 19(6): 506-12.
File SE, Fluck E, Fernandes C.

The N-methyl D-aspartate receptor complex is involved in the mechanism of long-term potentiation, which is thought to be the biological basis of learning and memory. This complex can be manipulated in a number of ways, one of which is through the strychnine-insensitive glycine receptor coagonist site. The effects of Bioglycin(Konapharma, Pratteln, Switzerland), a biologically active form of the amino acid glycine, were therefore studied in healthy students (mean age, 20.7 years) and middle-aged men (mean age, 58.9 years) with tests that measured attention, memory and mood, using a double-blind, randomized, crossover design. Compared with the young group, the middle-aged group had significantly poorer verbal episodic memory, focused, divided, and sustained attention; they also differed in their subjective responses at the end of testing. Bioglycin significantly improved retrieval from episodic memory in both the young and the middle-aged groups, but it did not affect focused or divided attention. However, the middle-aged men significantly benefited from Bioglycin in the sustained-attention task. The effects of Bioglycin differed from those of other cognitive enhancers in that it was without stimulant properties or significant effects on mood, and it primarily improved memory rather than attention. It is likely to be of benefit in young or older people in situations where high retrieval of information is needed or when performance is impaired by jet lag, shift work, or disrupted sleep. It may also benefit the impaired retrieval shown in patients with schizophrenia, Parkinson's disease, and Huntington's disease.


Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Arch Gen Psychiatry. 1999 Jan; 56(1): 29-36.
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.

BACKGROUND: Disturbances of N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission may play an important role in the pathophysiology of negative symptoms of schizophrenia. Glycine, a small nonessential amino acid, functions as an obligatory coagonist at NMDA receptors through its action at a strychnine-insensitive binding site on the NMDA receptor complex. Glycine-induced augmentation of NMDA receptor-mediated neurotransmission may thus offer a potentially safe and feasible approach for ameliorating persistent negative symptoms of schizophrenia.
METHODS: Twenty-two treatment-resistant schizophrenic patients participated in a double-blind, placebo-controlled, 6-week, crossover treatment trial with 0.8 g/kg per day of glycine added to their ongoing antipsychotic medication. Clinical assessments, including the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), the Simpson-Angus Scale for Extrapyramidal Symptoms, and the Abnormal Involuntary Movement Scale, were performed biweekly throughout the study. Clinical laboratory values and amino acid serum levels were monitored.
RESULTS: Glycine treatment was well tolerated and induced increased glycine (P=.001) and serine (P=.001) serum levels. Glycine administration resulted in (1) a significant (P<.001) 30%+/-16% reduction in negative symptoms, as measured by the PANSS, and (2) a significant (P<.001) 30%+/-18% improvement in the BPRS total scores. The improvement in negative symptoms was unrelated to alterations in extrapyramidal effects or symptoms of depression. Low pretreatment glycine serum levels significantly predicted (r= 0.80) clinical response.
CONCLUSION: These findings support hypoglutamatergic hypotheses of schizophrenia and suggest a novel approach for the pharmacotherapy of negative symptoms associated with this illness.


Stimulatory effect of glycine on human growth hormone secretion.
Metabolism. 1978 Feb; 27(2): 201-8.
Kasai K, Kobayashi M, Shimoda SI.

Glycine (250 ml 0.3 M glycine) was administered orally to 19 nonobese normal subjects and 12 subjects with partial gastrectomy. In the normal subjects, a clear and significant increase of serum human growth hormone (hGH) level was observed (p less than 0.001), whereas serum immunoreactive insulin (IRI), prolactin (PRL) and blood sugar (BS) levels were not affected after the drug administration. A more pronounced and significant increase of hGH value in serum was found in the subjects with gastrectomy than in the normal controls (p less than 0.001). Thus we administered the drug intraduodenally in normal subjects. The similar rise of hGH to that of the gastrectomied group was obtained in normals by this administration. The facts demonstrated that glycine is one of the stimulatory agents inducing the pituitary gland to secrete hGH. In addition, in nonobese diabetics, no significant increase of serum hGH level, even after the intraduodenal administration of glycine, was observed in the present study.


Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643.
Carcinogenesis. 1999 Nov; 20(11): 2075-81.
Rose ML, Cattley RC, Dunn C, Wong V, Li X, Thurman RG.

Previous studies demonstrated that dietary glycine prevents elevated rates of cell proliferation following treatment with the peroxisome proliferator and liver carcinogen WY-14,643. Since increased cell replication is associated with the development of hepatic cancer caused by peroxisome proliferators, glycine may have anti-cancer properties. Therefore, experiments were designed to test the hypothesis that dietary glycine would inhibit the hepatocarcinogenic effect of WY-14,643. Male F344 rats were fed four different NIH 07-based diets: 5% glycine; 5% valine for nitrogen balance (control); 0.1% WY-14,643 + 5% valine (WY-14,643); 0.1% WY-14,643 + 5% glycine (WY-14,643 + glycine). Food consumption did not differ among the groups, but WY-14,643-fed rats weighed 10-25% less than expected based on previous studies. Serum glycine levels were elevated 4-5-fold by glycine-containing diets; however, the 10-fold increase in peroxisomal enzyme activity caused by WY-14,643 was unaffected by the addition of 5% glycine to the diet. After 22 weeks, livers from rats fed WY-14,643 had a similar incidence and multiplicity of proliferative lesions (foci and adenomas) to those fed WY-14,643 + glycine. Moreover, cell proliferation in the surrounding 'normal' parenchyma (labeling index approximately 4%) and foci (labeling index approximately 50%) did not differ between WY-14,643 and WY-14,643 + glycine-fed rats. However, after 51 weeks of dietary exposure to WY-14,643, glycine prevented formation of small (0-5 mm diameter) tumors by 23% and inhibited the development of medium size (5-10 mm) tumors by 64%. Furthermore, glycine prevented the formation of the largest tumors (>10 mm) by nearly 80%. Thus, glycine did not inhibit early foci formation; however, it significantly decreased their ability to progress to tumors. Moreover, the inhibitory effect of glycine was greater with increasing tumor size. These studies demonstrate that dietary glycine prevents the development of hepatic tumors caused by the peroxisome proliferator WY-14,643 consistent with the idea that it may be an effective chemopreventive agent.

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide medical advice to individuals. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes. Any reproduction in whole or part and in print or electronic form without express permission is strictly forbidden. Permission to reproduce selected material may be granted by contacting AOR Inc.

Copyright © 2005, Advanced Orthomolecular Research

Insider Updates coming soon

Below are the questions and answers that have been assigned to this product. Click on the question to view its details.

Public FAQs

Q: How much vitamin D should I take everyday?
A: According to the latest research, 4000 -6000 IU of vitamin D is what is needed for optimal health. Unfortunately, Health Canada has banned the use of more than 1000 IU of vitamin D per day as a recommended dose in dietary supplements. Canadians wanting more must take several capsules or get a prescription.

Q: I Have Heard That Sorbitol Can Be Potentially Dangerous To Diabetics. Is This True?
A: No. The root of the question is not entirely without merit, however, since sorbitol is structurally a sugar alcohol. However, any problem posed by excess cellular sorbitol for diabetics is that it is actually caused by excess glucose in the cell (which is converted to sorbitol in the body), and this pertains to ENDOGENOUS sorbitol. When EXOGENOUS sorbitol is introduced from capsules, the liver converts this sorbitol into glucose, leading some to believe that this can have negative metabolic implications. However, much of this sorbitol (up to 75%) is converted to CO2 and is released as perspiration. Furthermore, the amount of sorbitol found in a typical capsule is approximately 8-14 mg, and even if the conversion to glucose was complete, this would lead to an increase of blood glucose levels of 300 mcg/dl. To put that number into proper perspective, normal fasting glucose levels are 140 mg/dl, and normal non-fasting levels are approximately 400 mg/dl. These numbers represent approximately one-466th and one- 1333rd respectively the difference the amount of sorbitol in a capsule could possibly make, a negligible number brought into even clearer perspective given the fact that most glucometers are accurate to within 10-15%. Adcock LH, Gray CH. The metabolism of sorbitol in the human subject. Biochem J. 1957 Mar;65(3):554-560.

Q: What is Sorbitol and Why Is It Used In AORs Capsules?
A: Sorbitol, also known as glucitol, is a highly ubiquitous and naturally-occurring substance found in everything from the biochemistry of the human body to apples to chewing gum. The latter of course contains the synthetic version, and in the supplement industry sorbitol is used in capsules, tablets and softgels. Its most common roles are that of a plasticizer (to reduce capsule brittleness and enhance stability) and as a humectant (to reduce long-term leakage). Sorbitol is one of the most effective and widely used substances in the world for these and other similar purposes, spanning the food, pharmaceutical, and natural supplement industries. It holds GRAS (Generally Recognized As Safe) status with the FDA in the United States and in Canada is listed on the Ministry of Health's list of Acceptable Non-medicinal Ingredients with a composition allowance of 90%, one of the highest of any non-medicinal ingredients. However, as of March of 2009, the capsules of AOR products will no longer contain sorbitol as a constituent.

Q: What is the difference between Ortho Bone and Bone Basics?
A: Ortho Bone is more complete is is recommended for those suffering from bone loss, osteopenia or osteoporosis. Bone Basics is an excellent formula and is great for those looking to maintain their bone health. the main difference between the two formulas is that the recommended dose for Ortho Bone is 10 capsules per day and 6 capsules per day for Bone Basics. Ortho Bone also contains more advanced forms of the nutrients it contains.

Q: Why should strontium be taken on an empty stomach?
A: The presence of food in the stomach reduces the bioavailability of Strontium from about 24% to 19%. Since Strontium is used for the treatment of osteoporosis and is typically used for several years, this can make a big difference vis a vis it's long term efficacy.